Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tissue RepairASX:TRP -1.19% EV-to-EBITDA is 0.50 as of Jul. 30, 2026, which is 6% above its 10-year median of 0.47. The stock has 1 warning sign investors should review. Among 410 Biotechnology companies, Tissue Repair ranks better than 83.9% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tissue Repair's enterprise value is A$-3.28 Mil.
Tissue Repair's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-6.56 Mil. Therefore, Tissue Repair's EV-to-EBITDA for today is 0.50.
The historical rank and industry rank for Tissue Repair's EV-to-EBITDA or its related term are showing as below:
ASX:TRP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.8 Med: 0.47 Max: 1.99
Current: 0.5
During the past 5 years, the highest EV-to-EBITDA of Tissue Repair was 1.99. The lowest was -1.80. And the median was 0.47.
ASX:TRP's EV-to-EBITDA is ranked better than 83.9% of 410
companies
in the Biotechnology industry
Industry Median: 11.46
vs ASX:TRP: 0.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Tissue Repair (ASX:TRP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tissue Repair's PE Ratio (TTM) for today is calculated as:
Tissue Repair's share price for today is A$0.083.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tissue Repair's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.064.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Tissue Repair's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:TRP vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Tissue Repair's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Repair EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Repair's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tissue Repair's EV-to-EBITDA falls into.
Tissue Repair's current Enterprise Value is A$-3.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tissue Repair's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-6.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Repair (ASX:TRP) has a EV-to-EBITDA of 0.50 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tissue Repair. This is near median its historical median of 0.47. According to the industry distribution chart, Tissue Repair ranks #66 out of 410 companies in the Biotechnology industry, placing it in the top 16.1%.
Is Tissue Repair's EV-to-EBITDA too high?
Tissue Repair's current EV-to-EBITDA of 0.50 is near median its 10-year median of 0.47. The Biotechnology industry median EV-to-EBITDA is 11.46. Tissue Repair's value of 0.50 is 95.6% below this industry median. Based on the distribution chart, Tissue Repair ranks #66 out of 410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Tissue Repair's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tissue Repair ranks #66 out of 410 companies for EV-to-EBITDA. This places Tissue Repair in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 11.46. Tissue Repair's value of 0.50 is 95.6% below this benchmark. While the company's 10-year median is 0.47 vs. the industry median of 11.46, Tissue Repair has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.46, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Repair's current EV-to-EBITDA of 0.50 is 95.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tissue Repair. For the Biotechnology industry, the median EV-to-EBITDA is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Repair's current EV-to-EBITDA is 0.50, which is near median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Repair stock overvalued right now?
Tissue Repair (ASX:TRP) has a current EV-to-EBITDA of 0.50. The current EV-to-EBITDA is 0.50, which is near median its 10-year median of 0.47 and 95.6% below the Biotechnology industry median of 11.46. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Tissue Repair (ASX:TRP), the current EV-to-EBITDA is 0.50 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tissue Repair Ltd is a clinical-stage biopharmaceutical company engaged in development of wound healing products for chronic wounds and the aftercare of cosmetic procedures, with the potential for further development of related technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRP has been successfully added to your 
